LSD1/KDM1A inhibition

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-04-02 — Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Phase I/II trial of seclidemstat (LSD1/KDM1A inhibitor) combined with azacitidine in MDS/CMML extends LSD1 + hypomethylating agent combination strategy to a second LSD1 inhibitor (beyond iadademstat/bomedemstat) in myeloid neoplasms adjacent to MPN. (novelty: 3)
• 2026-02-20 — Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis: Phase 2 trial of bomedemstat (LSD1 inhibitor) added to momelotinib in MF patients with suboptimal response or baseline cytopenias represents the first prospective test of LSD1 + JAK inhibition combination, extending LSD1 blockade beyond chronic-phase ET monotherapy and DNMT-combination paradigms into JAKi-augmentation territory. (novelty: 4)
• 2026-04-23 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007): Phase 3 MK-3543-007 trial tests bomedemstat (LSD1 inhibitor) head-to-head against hydroxyurea as first-line cytoreduction in ET, the first randomized challenge to standard-of-care using LSD1 blockade in chronic-phase MPN. (novelty: 4)
• 2026-04-28 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs): cross-connection with dna-hypomethylation-epigenetic-reprogramming: The ASTX727 + iadademstat trial directly couples DNA hypomethylation with LSD1 inhibition, proposing combined epigenetic reprogramming as a therapeutic axis in advanced MPN. (novelty: 4)
• 2026-04-13 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs): Iadademstat is being tested as an add-on LSD1 inhibitor to ASTX727 in advanced MPN, the first randomized evaluation of LSD1 blockade in accelerated/blast phase Ph-negative MPN. (novelty: 4)

Open questions

Related mechanisms